Conversion disorder

disease
On this page

Also known as conversion hysterical neurosisFNDfunctional movement disorderfunctional neurological disorder

Summary

Conversion disorder (MONDO:0002104) is a disease and 65 clinical trials. Top therapeutic interventions include sertraline. A subtype of somatoform disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 65

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameconversion disorder
Mondo IDMONDO:0002104
MeSHD003291
DOIDDOID:1768
UMLSC0009946
MedGen3230
Is cancer (heuristic)no

Also known as: conversion hysterical neurosis · FND · functional movement disorder · functional neurological disorder

Disease family

This is a subtype of somatoform disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disordersomatoform disorderconversion disorder

Related subtypes (5): body dysmorphic disorder, neurocirculatory asthenia, hypochondriasis, somatization disorder, physiological malfunction arising from mental factor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 65.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified61
PHASE42
PHASE1/PHASE21
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00159965PHASE4COMPLETEDTreatments for Psychogenic Nonepileptic Seizures (NES)
NCT00835627PHASE4COMPLETEDTreatment Trial for Psychogenic Nonepileptic Seizures
NCT05155059PHASE2ACTIVE_NOT_RECRUITINGNon-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders
NCT01422278PHASE1/PHASE2UNKNOWNRehabilitation of Conversion Gait Disorder
NCT04097184Not specifiedRECRUITINGEfficacy of Dorso-lateral Prefrontal Cortex Stimulation by tDCS in Motor Conversion Disorder Patients
NCT04662372Not specifiedACTIVE_NOT_RECRUITINGFunctional Neurological Disorders in Patients Admitted in Stroke Units
NCT05723276Not specifiedACTIVE_NOT_RECRUITINGPsilocybin in Functional Neurological Disorder
NCT05943652Not specifiedRECRUITINGObservational Study on Functional Overlay in Patients With Movement Disorders
NCT06257069Not specifiedACTIVE_NOT_RECRUITINGTremor Retrainer Software Application for Functional Tremor
NCT06362161Not specifiedRECRUITINGEstablishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND
NCT06393439Not specifiedRECRUITINGVirtual Reality in Functional Movement Disorder
NCT06422819Not specifiedRECRUITINGClinical Evaluation of HRV Biofeedback in Functional Neurological Disorders Compared to Placebo
NCT06439017Not specifiedNOT_YET_RECRUITINGPassive Thoughts in Functional Movement Disorders
NCT06726135Not specifiedNOT_YET_RECRUITINGThe NRC Dataset. Developing a Minimum Dataset for Multidisciplinary Rehabilitation: a Modified E-Delphi Study
NCT06792760Not specifiedENROLLING_BY_INVITATIONAdditive Effects of Interoceptive Training to Physiotherapy in Functional Movement Disorders (interoPTfmd)
NCT06872788Not specifiedNOT_YET_RECRUITINGStudy of Sensory Attenuation in Functional Movement Disorders
NCT06873698Not specifiedRECRUITINGPilot Neurobehavioral Therapy for Functional Neurological Disorder
NCT07006415Not specifiedNOT_YET_RECRUITINGBrain-computer Interface Rehabilitation And Virtual Environments in Functional Neurological Disorder (BRAVE-FND)
NCT07077603Not specifiedNOT_YET_RECRUITINGThe Feasibility and Acceptability of an Online Yoga Program for People With Functional Neurological Disorders
NCT07302308Not specifiedNOT_YET_RECRUITINGAction Outcome Latencies as a Measure of Sense of Agency in Functional Movement Disorders.
NCT07372755Not specifiedNOT_YET_RECRUITINGFeasibility and Usability of a Mobile App for Monitoring and Managing Functional Movement Disorders
NCT07378488Not specifiedRECRUITINGDance/Movement Therapy for Functional Neurological Disorder
NCT07478666Not specifiedRECRUITINGFeasibility of Remotely Measured Activity Behavior for Individuals With Functional Neurologic Disorder
NCT07527403Not specifiedRECRUITINGImpact of Theta Burst Repetitive Transcranial Magnetic Stimulation on the Patient’s Self-reported Improvement in Their Motor Functional Neurological Disorder
NCT07538414Not specifiedRECRUITINGInvestigation of Patients Presenting With Acute Functional Neurological Symptoms
NCT07588282Not specifiedRECRUITINGThe Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intentions Among Patients With Functional Neurological Movement Disorders
NCT00448084Not specifiedCOMPLETEDBrain Activity in People With Functional Movement Disorders
NCT00971360Not specifiedCOMPLETEDCytokine Levels in Conversion Disorder
NCT02102906Not specifiedCOMPLETEDTMS and Attentional Bias in Functional Motor Disorder
NCT02275000Not specifiedCOMPLETEDFeasibility Study of Physiotherapy for Functional Motor Symptoms
NCT02325544Not specifiedCOMPLETEDComparing Different Treatments in Reducing Dissociative Seizure Occurrence
NCT02329626Not specifiedCOMPLETEDMetabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder
NCT02764476Not specifiedTERMINATEDEmbodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder
NCT02905877Not specifiedCOMPLETEDThe Pathophysiology of Functional Neurological Disorders
NCT03325374Not specifiedCOMPLETEDBLB Study Back or Leg Pain and Bladder Symptoms Study
NCT03398070Not specifiedCOMPLETEDNeuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
NCT03441867Not specifiedUNKNOWNNeuroimaging Biomarker for Seizures
NCT03660098Not specifiedCOMPLETEDMirror Box Therapy As a Treatment Option for Functional Movement Disorders
NCT03661021Not specifiedCOMPLETEDStudy of the Ability of a New Technique to Effectively Diagnose Movement Disorders
NCT03717376Not specifiedCOMPLETEDMovement Disorders and Early Maladaptive Schemas

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
SERTRALINE42
CHEMBL178836102